Vir Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vir Biotechnology, Inc. on June 9, 2026. The report discloses corporate governance changes effective immediately as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Appointment: Timothy Coughlin, CPA, was appointed as a Class III director, serving until the 2028 annual meeting of stockholders.
- Committee Role: Mr. Coughlin was appointed as Chair of the Audit Committee.
- Compensation: Mr. Coughlin received standard non-employee director compensation, including stock options and restricted stock units under the 2019 Equity Incentive Plan, pursuant to the automatic grant program.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No risks, contingencies, or unusual items were disclosed in this specific report. The appointment was not made pursuant to any arrangement with any person, and no related party transactions subject to disclosure under Item 404(a) of Regulation S-K exist.
Key Facts for Investor Verification
- Verify the terms of the 2026 Proxy Statement regarding the specific amounts of cash and equity compensation for non-employee directors.
- Confirm the vesting schedules and terms for the stock options and restricted stock units granted to Mr. Coughlin under the 2019 Equity Incentive Plan.
- Review the standard form of indemnity agreement filed as Exhibit 10.1 to the Company's Form S-1 (File No. 333-233604).